Chronic pelvic pain and cannabis: pain arising from multiple sources

Chronic pelvic pain is a syndrome, not a single diagnosis

Pelvic pain that persists for six months or longer can have many overlapping causes: endometriosis, adenomyosis, bladder pain, bowel disorders, pelvic-floor muscle dysfunction, nerve conditions or combinations of these. Some people experience pain without one clearly identifiable organ explaining everything. The uterus, ovaries, bladder, bowel, muscles and nerves occupy a small space and share pathways to the spinal cord and brain. A useful assessment therefore asks where pain began, what now maintains it, and how much daily function is affected.

The nervous system may amplify persistent pain

Prolonged input from an inflamed or painful tissue may contribute to central sensitization, in which the nervous system becomes more responsive to signals. Cross-sensitization describes how input from one pelvic organ may influence sensitivity in another through shared neural pathways. These mechanisms help explain persistent pain; they do not mean that the pain is imagined. Pain is real whether a clearly visible lesion is found or not, and mechanisms can differ greatly between individuals.

Why cannabinoid signaling attracts researchers

CB1 receptors are involved in pain signaling in peripheral nerves, spinal circuits and the brain. CB2 and related pathways may interact with immune activity and inflammation. The endocannabinoid system is also studied in stress responses and sleep. That creates several possible symptom targets, but it does not mean that cannabis treats the underlying gynecologic disease, corrects pelvic-floor dysfunction or provides a reliable anti-inflammatory effect in patients.

What patient surveys actually tell us

Observational studies discussed by ACOG report that some patients with endometriosis or other chronic pelvic pain use cannabis. In one setting, roughly 15% of patients with endometriosis and 14% with other forms of chronic pelvic pain reported use. In a small survey, about 23% used cannabis, with some reporting less pain, cramping or muscle tension and better sleep. Reviews of observational reports describe high proportions of users perceiving relief, but the studies use very different products, doses and questions.

Patient-reported relief is not proof of drug efficacy

People who choose a product for themselves are not randomized to it. There may be no placebo comparison, and the sample may overrepresent people who continue using it because they feel better. A favorable report may be meaningful for the individual, yet it cannot identify the true average treatment effect or show that a THC–CBD combination is superior. The American College of Obstetricians and Gynecologists concluded in its 2024 consensus that data were insufficient to make a recommendation on the use of cannabis products for pain associated with gynecologic conditions.

Less pain does not necessarily mean less disease

Suppose someone with endometriosis reports substantially less pain after taking a cannabinoid. That improvement deserves to be taken seriously, but it does not establish that lesions have shrunk, adhesions have resolved or fertility has improved. The treatment target may be pain processing, sleep or distress rather than the source of tissue disease. Symptom management and disease treatment should be evaluated separately.

Pelvic-floor muscles, sleep and the wider pain cycle

Pain may lead to protective muscle contraction, and prolonged contraction can itself be painful. Interrupted sleep and stress may increase pain sensitivity. Some users report relief in several of these domains, but clinical trials have not established whether cannabinoids directly relax the pelvic floor or which patients might benefit. A comprehensive plan can involve gynecologic assessment, pelvic floor physical therapy, evidence-based pain care, sleep support and attention to emotional well-being.

Safety, pregnancy planning and a realistic conclusion

Dry mouth, drowsiness, intoxication, impaired driving and drug interactions all matter. Pregnancy or conception planning adds particular caution. Cannabis should not delay evaluation of new, worsening or unexplained pelvic pain. The current evidence supports studying cannabinoids and listening carefully to patient experience, but it does not justify describing cannabis as a proven standard treatment for chronic pelvic pain or the diseases causing it.

Original references and Hebrew article

This article is an editorial adaptation of the Hebrew original.

1. American College of Obstetricians and Gynecologists. The Use of Cannabis Products for the Management of Pain Associated With Gynecologic Conditions. 2024. Find publication ↗
2. Liang AL, et al. Medical Cannabis for Gynecologic Pain Conditions: A Systematic Review. Obstetrics & Gynecology. Find publication ↗
3. Johnson S, et al. Biopsychosocial Approaches for the Management of Female Chronic Pelvic Pain: A Systematic Review. BJOG. 2025. Find publication ↗
4. ACOG 2024 clinical consensus on gynecologic pain Find publication ↗

Read original Hebrew article ↗

Educational information only. This page is not a diagnosis or a treatment recommendation. Do not alter prescribed care without consulting the treating clinician, especially in neurological illness, fertility planning or pregnancy.